Febrile Neutropenia
1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GS
AstellasChina - Shenyang
1 programCaspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and NeutropeniaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Gilead SciencesLiposomal amphotericin B
Coherus OncologyPegfilgrastim-Cbqv
AstellasCaspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Clinical Trials (3)
Total enrollment: 543 patients across 3 trials
Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics
Start: Mar 2007Est. completion: May 200820 patients
Phase 4Terminated
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Start: Aug 2020Est. completion: Dec 2022200 patients
N/AUnknown
NCT00723073AstellasCaspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Start: Jan 2008Est. completion: May 2008323 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space